Heightened interest in therapeutic efficiency, quality and safety of food supply, as well as increasing concerns about environmental contamination, drive the biotechnology market. Biopharmaceuticals is poised to experience spiraling growth given the recent success of commercialized products and the steady stream of products presently in the pipeline.
San Jose, California (PRWEB) September 11, 2008 -- Biotechnology industry is regarded as one of the most capital intensive and research-intensive industries. Competitive success and growth in the industry is hugely dependent on the ability to secure needed capital. Majority of companies cannot pivot on product revenues to meet these needs because of the time required to bring new products to market. Instead, the industry has used a wide variety of mechanisms, ranging from venture capital investments and public investments, joint ventures and partnerships with other companies to pump the money required to fuel the industry's growth. Regulation will also continue to remain a key factor influencing the growth of the biotechnology industry, especially for recombinant DNA technology based products. In the upcoming years, the world biotechnology industry is expected to make substantial progress fueled by private funding, collaborative research communities, and commercial opportunities.
Biotechnology has been recognized as a key growth technology by most industrialized countries. While the United States industry leads the global http://www.strategyr.com/Biotechnology_Industry_Market_Report.asp [biotechnology market] in terms of discovery and product sales, Japan, Asia and the Europe are coordinating government, academic and industrial resources in biotechnology development to establish a strong, government-supported technology network.
Copyright©2008 Vocus, Inc.
All rights reserved